United Laboratories International Holdings Ltd.HKEX: 3933

The group's product Semaglutide Injection marketing registration application been accepted

· Issued by United Laboratories International Holdings Ltd. via HKEXnews

Filed with HKEX · Stock code 3933 · · 2 pages · English

Summary by 6ix AI

United Laboratories International Holdings Ltd. announced that its marketing registration application for Semaglutide Injection has been accepted by the China National Medical Products Administration. The acceptance of this application broadens the product's indication portfolio and aims to benefit a wider patient population. The company plans to continue investing in research and development to enhance its competitiveness in the biopharmaceutical sector.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

United Laboratories International Holdings Ltd. on 6ix

Earlier from United Laboratories International

Later from United Laboratories International

All United Laboratories International news releases